Fat cells play key role in Melanoma

Written on |

Fat cells allow melanoma cells to penetrate the dermis, from which they spread, causing fatal metastases in vital organs, TAU researchers say

Researchers at Tel Aviv University, led by Prof. Carmit Levy and Dr. Tamar Golan of the Department of Human Genetics and Biochemistry at TAU’s Sackler School of Medicine, have discovered that fat cells are involved in the transformation that melanoma cells undergo from cancer cells of limited growth in the epidermis to lethal metastatic cells attacking patients’ vital organs.

“We have answered a major question that has preoccupied scientists for years,” explains Prof. Levy. “What makes melanoma change form, turning aggressive and violent? Locked in the skin’s outer layer, the epidermis, melanoma is very treatable; it is still Stage 1, it has not penetrated the dermis to spread through blood vessels to other parts of the body and it can simply be removed without further damage.

“Melanoma turns fatal when it ‘wakes up,’ sending cancer cells to the dermis layer of skin, below the epidermis, and metastasizing in vital organs. Blocking the transformation of melanoma is one of the primary targets of cancer research today, and we now know fat cells are involved in this change.”

The research was conducted in collaboration with several senior pathologists: Dr. Hanan Vaknin of Wolfson Medical Center, and Dr. Dov Hershkowitz and Dr. Valentina Zemer of Tel Aviv Medical Center.

The study was on published July 23 in Science Signaling and is featured on the journal’s cover.

In the study, the researchers examined dozens of biopsy samples taken from melanoma patients at Wolfson Medical Center and Tel Aviv Medical Center, and observed a suspicious phenomenon: fat cells near the tumor sites.

“We asked ourselves what fat cells were doing there and began to investigate,” adds Prof. Levy. “We placed the fat cells on a petri dish near melanoma cells and followed the interactions between them.”

The researchers observed fat cells transferring proteins called cytokines, which affect gene expression, to the melanoma cells.

“Our experiments have shown that the main effect of cytokines is to reduce the expression of a gene called miRNA211, which inhibits the expression of a melanoma receptor of TGF beta, a protein that is always present in the skin,” says Prof. Levy. “The tumor absorbs a high concentration of TGF beta, which stimulates melanoma cells and renders them aggressive.”

Critically, the researchers have also found a way to block this transformation.

“It is important to note that we found the process reversible in the laboratory: When we removed the fat cells from the melanoma, the cancer cells calmed down and stopped migrating,” adds Prof. Levy.

A trial of mouse models of melanoma yielded similar results: When miRNA211 was repressed, metastases were found in other organs, while re-expressing the gene blocked metastases formation.

In the search for a potential drug based on the new discovery, the researchers experimented with therapies that are known to inhibit cytokines and TGF beta, but which have never before been used to treat melanoma.

“We are talking about substances that are currently being studied as possible treatments for pancreatic cancer, and are also in clinical trials for prostate, breast, ovarian and bladder cancers,” Dr. Golan said. “We saw that they restrained the metastatic process, and that the melanoma returned to its relatively ‘calm’ and dormant state.”

“Our findings can serve as a basis for the development of new drugs to halt the spread of melanoma — therapies that already exist, but were never used for this purpose,” concludes Prof. Levy. “In the future, we are seeking to collaborate with drug companies to enhance the development of the metastatic melanoma prevention approach.”

 

Image captions:

Fat cells allow melanoma cells to penetrate the dermis, from which they spread, causing fatal metastases in vital organs, TAU researchers say

Researchers at Tel Aviv University, led by Prof. Carmit Levy and Dr. Tamar Golan of the Department of Human Genetics and Biochemistry at TAU’s Sackler School of Medicine, have discovered that fat cells are involved in the transformation that melanoma cells undergo from cancer cells of limited growth in the epidermis to lethal metastatic cells attacking patients’ vital organs.

“We have answered a major question that has preoccupied scientists for years,” explains Prof. Levy. “What makes melanoma change form, turning aggressive and violent? Locked in the skin’s outer layer, the epidermis, melanoma is very treatable; it is still Stage 1, it has not penetrated the dermis to spread through blood vessels to other parts of the body and it can simply be removed without further damage.

Images:

Top: Nano-vaccine mechanism of action: following injection, the nano-vaccine internalizes into immune cells, leading to activation of T cells to recognize and attack melanoma.

Bottom: Prof. Carmit Levy (left) and Dr. Tamar Golan.

Credit for both: Prof. Carmit Levy/AFTA

 

Related posts

Hyperbaric Treatment More Effective than Medicines for Fibromyalgia Caused by Head Injury

24 March 2023

Promoting Women in Medicine

9 March 2023

#TAU_WOMEN_POWER

7 March 2023

Researchers Discover Mechanism that Facilitates Formation of Brain Metastases

27 February 2023

Light Pollution is Killing Desert Rodents

10 February 2023

Three Tel Aviv University Researchers Awarded the ERC Proof of Concept (PoC) grants

9 February 2023

Researchers Identify A New Genetic Risk Factor for Age-related Eye Disease

8 February 2023

People With Autism Experience Pain at a Higher Intensity

31 January 2023

Researchers Uncover New Factors Linked to Williams Syndrome

24 January 2023

Lessons in Tolerance and DNA Extraction in Tel Aviv University’s Medical Labs

18 January 2023

Medical Clowns – No Laughing Matter

18 January 2023

Tel Aviv University’s First MedTech Hackathon Sets a High Bar

15 January 2023

Researchers use Smartwatches to Measure Safety of COVID Vaccine

28 December 2022

Tel Aviv University Establishes Multidisciplinary Center for Research of Autoimmune Diseases

18 December 2022

Breakthrough in the Field of Controlled Drug Delivery

16 December 2022

Common Medications May Reduce Risk of Metastases after Colon and Rectal Cancer

9 December 2022

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: office@aftau.asn.au

New South Wales

Level 22, Westfield Tower 2, 101 Grafton Street, Bondi Junction NSW 2022
Phone: +61 418 465 556
Email: davidsolomon@aftau.org.au

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: clivedonner@thelinqgroup.com